About O11 biomedical

O11 biomedical, a visionary medical technology start-up that emerged as part of BioTex at RWTH Aachen University/ University Hospital Aachen 2022, aims to improve survival rates and quality of life for patients struggling with severe respiratory distress. O11 has developed a disruptive therapy that allows patients to "breathe out" carbon dioxide via the intestines, freeing them from hours of agonizing ventilation therapy: RESPILIQ™. With currently 6 employees and its own production and development facility in Aachen, O11 is ideally positioned for the future.

Press releases

Press

12. March 2024

Breathing through the gut: MedTech startup O¹¹ biomedical secures EIC Accelerator Grant and seed funding to accelerate growth.

Aachen-based MedTech start-up O11 uses the human gut as an alternative respiratory organ to improve the survival rate and quality of life of patients with severe respiratory distress. O11 successfully closed a seed financing round with High-Tech Gründerfonds and secured an EIC Accelerator Grant. Product RESPILIQ is rapidly approaching market approval. Aachen, March 12, 2024 – Aachen-based medical technology start-up O11 biomedical GmbH secured its first seed finan